Flow cytometry is a laser-based biophysical innovation utilized in protein designing, biomarker identification, cell arranging, and cell tallying. It is needed to a lead study identified with the blood. Flow cytometry examines the substance and actual attributes of the particles present in the blood. It is utilized to analyze wellbeing problems, for example, HIV and malignancy alongside a few applications in essential exploration, clinical preliminaries, and clinical practice. Flow cytometry is broadly utilized for assessing fringe blood, bone marrow, and other body liquids. Additionally, it gives fast examination of numerous qualities of single cells. The interaction discovers application in microbiology, immunology, hematology, cytology, and among other exploration fields.
The increasing prevalence of chronic diseases worldwide and the need for rapid, accurate, and sensitive prognosis techniques for disease validation are expected to propel the growth of the flow cytometry market. According to the World Health Organization (WHO), chronic diseases are the leading cause of death worldwide. Moreover, increasing technological advancements (as flow cytometry is quite an unexplored field) and the introduction of advanced methods such as improved cell sorting, higher resolution, rapid detection, and multifunctional analysis, ensuring enhanced efficiency in identifying and characterizing novel drugs are also expected to augment the market growth.
For instance, in 2017, the United States Food Drug and Administration (FDA) approved the use of a flow cytometer in the detection of lymphoma and leukemia cancer (blood cancer). In 2019, about 76,200 Americans were expected to be diagnosed with myeloma, lymphoma, or leukemia cancer, according to the Leukemia and Lymphoma Society. Moreover, in 2020, around 60,530 people are expected to be diagnosed with leukemia. Furthermore, the growing prevalence of cancer and HIV are expected to foster the flow cytometry market growth.
The rise in the development of new products is expected to create significant opportunities for the key players operating in the market. For instance, in 2019, Agilent Technologies launched the Agilent NovoCyte Advanteon flow cytometer at the International Society for Advancement of Cytometry. In terms of geography, the flow cytometry market is divided into six regions, such as North America, Europe, Asia Pacific, South America, the Middle East, and Africa. Key players are focused on launching technologically advanced products in the market. For instance, in 2019, Becton, Dickinson and Company (BD) launched BD an automated flow cytometer, FACSDuet to improve their efficiency by reducing errors. Furthermore, in April 2018, Merck launched a compact, customizable flow cytometer, CellStream Benchtop.
No comments:
Post a Comment